The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid a steady flow of institutional capital into the defensive healthcare sector, Meiji Yasuda America has disclosed significant new positions in industry leaders. The firm invested $4.7 million in Boston Scientific by purchasing 49,376 shares and acquired a $1.91 million stake in Vertex Pharmaceuticals during the fourth quarter. These investments highlight institutional confidence in the growth trajectories of medical technology and biotech firms despite recent sector volatility.
This institutional expansion comes as the healthcare sector shows mixed momentum; Vertex Pharmaceuticals reported a 7% increase in Q4 revenue to $2.52 billion according to company filings, while Boston Scientific navigates pressure following a guidance adjustment. Compared to peers, VRTX continues to trade at premiums reflecting its dominance in cystic fibrosis treatments, and the entry of Meiji Yasuda provides a supportive floor for both stocks per market data.
Sign in to access this content
Sign InTraders should monitor current price levels, with BSX closing at $47.17 and VRTX at $445.04 (close June 11, 2026). Looking ahead, sector sentiment may be influenced by upcoming macro data, following the US Unemployment Rate holding steady at 4.3% in the June 5 report. Support levels for Boston Scientific near $46.91 will be critical for assessing whether this institutional buying interest can sustain a technical floor.